Financials data is unavailable for this security.
View more
Year on year Percheron Therapeutics Ltd 's revenues fell -39.71% from 615.48k to 371.09k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 11.92m to a larger loss of 14.92m.
| Gross margin | -- |
|---|---|
| Net profit margin | -4,021.00% |
| Operating margin | -4,402.30% |
| Return on assets | -110.67% |
|---|---|
| Return on equity | -154.10% |
| Return on investment | -153.98% |
More ▼
Cash flow in AUDView more
In 2025, cash reserves at Percheron Therapeutics Ltd fell by 1.70m. Cash Flow from Financing totalled 13.95m or 3,759.67% of revenues. In addition the company used 15.64m for operations while cash used for investing totalled 7.24k.
| Cash flow per share | -0.0145 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.0092 |
|---|---|
| Tangible book value per share | 0.0092 |
More ▼
Balance sheet in AUDView more
| Current ratio | 5.10 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.0026 |
|---|---|
| Total debt/total capital | 0.0026 |
More ▼
